XML 29 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information (Tables)
 3 Months Ended
Jul. 31, 2016
Segment Reporting [Abstract]  
Summary of Segment Activity
The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands):
Three Months Ended July 31, 2016
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
511

 
$
3,159

 
$
—

 
$
3,670

Direct cost of services
 
(472
)
 
(2,005
)
 
—

 
(2,477
)
Sales and marketing costs
 
(141
)
 
(616
)
 
—

 
(757
)
Other operating expenses
 
—

 
(1,126
)
 
(704
)
 
(1,830
)
Stock- based compensation expense (1)
 
—

 
—

 
(1,129
)
 
(1,129
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(102
)
 
$
(588
)
 
$
(1,833
)
 
$
(2,523
)
 
Three Months Ended July 31, 2015
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
485

 
$
2,337

 
$
—

 
$
2,822

Direct cost of services
 
(634
)
 
(1,588
)
 
—

 
(2,222
)
Sales and marketing costs
 
(332
)
 
(577
)
 
—

 
(909
)
Other operating expenses
 
—

 
(933
)
 
(880
)
 
(1,813
)
Stock- based compensation expense (1)
 
—

 
—

 
(775
)
 
(775
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(481
)
 
$
(761
)
 
$
(1,655
)
 
$
(2,897
)
 
(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments. See Note 3 for the allocation of stock compensation expense relative to the individual line items as it is reported on the Company's Consolidated Statements of Operations.